Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.

Characteristics and thrombogenicity of prothrombin complex concentrates.

Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates.

Prothrombin complex concentrates and coagulation.

[Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates (author's transl)].

Letter: Prothrombin-complex concentrates in liver disease.

Post-transfusion hepatitis after prothrombin complex concentrates.

Prothrombin complex concentrates in trauma and perioperative bleeding.

Compositional differences in commercially available prothrombin complex concentrates.

Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Letter: Prothrombin complex concentrates and chronic liver disease.

Infusion of clotting factor concentrates in haemophilia.

Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.

Comparison of different prothrombin complex concentrates--in vitro and in vivo studies.

The role of prothrombin complex concentrates in reversal of target specific anticoagulants.

Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal.

Response to letter to the editor: prothrombin complex concentrates in warfarin-associated intracranial hemorrhage.

Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery.

Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.

Influence of washing conditions on effective components of prothrombin complex concentrates.

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.

Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.

Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Laboratory and clinical evaluation of concentrates for treatment of haemophilia.

Suggest Documents

Characteristics and thrombogenicity of prothrombin complex concentrates.

Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates.

Prothrombin complex concentrates and coagulation.

[Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates (author's transl)].

Letter: Prothrombin-complex concentrates in liver disease.

Post-transfusion hepatitis after prothrombin complex concentrates.

Prothrombin complex concentrates in trauma and perioperative bleeding.

Compositional differences in commercially available prothrombin complex concentrates.

Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Letter: Prothrombin complex concentrates and chronic liver disease.

Infusion of clotting factor concentrates in haemophilia.

Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.

Comparison of different prothrombin complex concentrates--in vitro and in vivo studies.

The role of prothrombin complex concentrates in reversal of target specific anticoagulants.

Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal.

Response to letter to the editor: prothrombin complex concentrates in warfarin-associated intracranial hemorrhage.

Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery.

Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.

Influence of washing conditions on effective components of prothrombin complex concentrates.

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.

Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.

Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Laboratory and clinical evaluation of concentrates for treatment of haemophilia.

Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.

Recommend Documents

Follow Us